Phase III trial of divarasib versus adagrasib or sotorasib in KRAS G12C-m NSCLC

Shirish Gadgeel, MD, Henry Ford Cancer Institute/Henry Ford Health, Detroit, MI, discusses a Phase III trial (EudraCT: 2024-510908-37-00) of divarasib, an oral KRAS G12C inhibitor, compared to adagrasib or sotorasib in patients with previously treated KRAS G12C-mutated advanced/metastatic non-small cell lung cancer (NSCLC). Divarasib has demonstrated promising antitumor activity with an acceptable safety profile in previous studies. The primary endpoint in this trial will be progression-free survival. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.